The small-molecule inhibitor cabozantinib inhibits the activity of multiple receptor tyrosine kinases, including MET and vascular endothelial growth factor receptor (VEGFR), resulting in the inhibition of tumour angiogenesis and metastasis.6 This evidence concerns the gene MET and neoplasm.